T-cell therapies for HIV

Immunotherapy

Volumn 5, Issue 4, 2013, Pages 407-414

  Lam, Sharon ^a,b,c   Bollard, Catherine ^a,b,c,d  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b Texas Children's Cancer and Hematology Centers   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

adoptive T cell therapy; adoptive T cell transfer; antiretroviral therapy; ART; CAR; chimeric antigen receptor; zinc finger nuclease

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; DRUG EFFICACY; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE TRANSFER; NEOPLASM; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANTI-HIV AGENTS; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE;

EID: 84875959697     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.23     Document Type: Review

References (50)

1. Leen AM, Myers GD, Sili U et al. Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160-1166 (2006).
2. Koenig S, Conley AJ, Brewah YA et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1(4), 330-336 (1995).
3. Lieberman J, Skolnik PR, Parkerson GR 3rd et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)- specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 90(6), 2196-2206 (1997).
4. Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb. Perspect. Med. 1(1), a007252 (2011).
5. Walker BD, Chakrabarti S, Moss B et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328(6128), 345-348 (1987).
6. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68(7), 4650-4655 (1994).
7. Saksena NK, Wu JQ, Potter SJ, Wilkinson J, Wang B. Human immunodeficiency virus interactions with CD8+ T lymphocytes. Curr. HIV Res. 6(1), 1-9 (2008).
8. Le Borgne S, Fevrier M, Callebaut C, Lee SP, Riviere Y. CD8(+)-cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription. J. Virol. 74(10), 4456-4464 (2000).
9. Saez-Cirion A, Lacabaratz C, Lambotte O et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104(16), 6776-6781 (2007).
10. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: How do they tame the virus? Trends Immunol. 28(12), 532-540 (2007).
11. Kinter A, Mcnally J, Riggin L, Jackson R, Roby G, Fauci AS. Suppression of HIVspecific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc. Natl Acad. Sci. USA 104(9), 3390-3395 (2007).
12. Goonetilleke N, Liu MK, Salazar-Gonzalez JF et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206(6), 1253-1272 (2009).
13. Addo MM, Yu XG, Rathod A et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77(3), 2081-2092 (2003).
14. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006).
15. Miura T, Brockman MA, Schneidewind A et al. HLA-B57/B.*5801 human immunodeficiency virus type 1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 83(6), 2743-2755 (2009).
16. Ndhlovu ZM, Proudfoot J, Cesa K et al. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J. Virol. 86(12), 6959-6969 (2012).
17. Pitcher CJ, Quittner C, Peterson DM et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5(5), 518-525 (1999).
18. Mackay CR. Dual personality of memory T cells. Nature 401(6754), 659-660 (1999).
19. Cruz CR, Hanley PJ, Liu H et al. Adverse events following infusion of T cells for adoptive immunotherapy: A 10-year experience. Cytotherapy 12(6), 743-749 (2010).
20. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925-935 (2010).
21. Crowe SM, Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: A further obstacle to eradication. J. Leukocyte Biol. 68(3), 345-350 (2000).
22. Di Stasi A, Tey SK, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
23. Cohen GB, Gandhi RT, Davis DM et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10(6), 661-671 (1999).
24. Lundquist CA, Tobiume M, Zhou J, Unutmaz D, Aiken C. Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J. Virol. 76(9), 4625-4633 (2002).
25. Ganusov VV, Goonetilleke N, Liu MK et al. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J. Virol. 85(20), 10518-10528 (2011).
26. Varela-Rohena A, Molloy PE, Dunn SM et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14(12), 1390-1395 (2008).
27. Mitsuyasu RT, Anton PA, Deeks SG et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta genemodified autologous CD4(+) and CD8(+)T cells in human immunodeficiency virusinfected subjects. Blood 96(3), 785-793 (2000).
28. Deeks SG, Wagner B, Anton PA et al. A Phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5(6), 788-797 (2002).
29. Scholler J, Brady TL, Binder-Scholl G et al. Decade-long safety and function of retroviralmodified chimeric antigen receptor T cells. Sci. Transl. Med. 4(132), 132ra153 (2012).
30. Heslop HE. Safer CARS. Mol. Ther. 18(4), 661-662 (2010).
31. Van Gulck ER, Vanham G, Heyndrickx L et al. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by Gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J. Virol. 82(7), 3561-3573 (2008).
32. De Keersmaecker B, Allard SD, Lacor P, Schots R, Thielemans K, Aerts JL. Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J. Virol. 86(17), 9351-9360 (2012).
33. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118(1), 294-305 (2008).
34. Chapuis AG, Casper C, Kuntz S et al. HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood 117(20), 5391-5402 (2011).
35. Kolte L, Gaardbo JC, Skogstrand K, Ryder LP, Ersboll AK, Nielsen SD. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs. Clin. Exp. Immunol. 155(1), 44-52 (2009).
36. Dai B, Xiao L, Bryson PD, Fang J, Wang P. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Mol. Ther. 20(9), 1800-1809 (2012).
37. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
38. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
39. Wiesel M, Oxenius A. From crucial to negligible: Functional CD8(+) T-cell responses and their dependence on CD4(+)T-cell help. Eur. J. Immunol. 42(5), 1080-1088 (2012).
40. Koretzky GA. Multiple roles of CD4 and CD8 in T cell activation. J. Immunol. 185(5), 2643-2644 (2010).
41. Hutter G, Nowak D, Mossner M et al. Longterm control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692-698 (2009).
42. Cannon P, June C. Chemokine receptor 5 knockout strategies. Curr. Opin. HIV AIDS 6(1), 74-79 (2011).
43. Anderson JS, Walker J, Nolta JA, Bauer G. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: A novel method for targeted gene therapy and intracellular immunization. J. Acquir. Immune Defic. Syndr. 52(2), 152-161 (2009).
44. Kim SS, Peer D, Kumar P et al. RNAimediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol. Ther. 18(2), 370-376 (2010).
45. Yuan J, Wang J, Crain K et al. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol. Ther. 20(4), 849-859 (2012).
46. Anderson JS, Javien J, Nolta JA, Bauer G. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol. Ther. 17(12), 2103-2114 (2009).
47. Pritchard J. The side effects of HAART (2010). www.livestrong.com/ article/249257-the-sideeffects- of-haart 102 Redirected high affinity Gag-specific autologous T cells for HIV gene therapy. www.clinicaltrials.gov/ ct2/show/ NCT00991224
48. Phase 1 dose escalation study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected patients. www.clinicaltrials.gov/ct2/show/ NCT01044654 Autologous T-Cells genetically modified at the CCR5 gene by zinc finger nucleases SB-728 for HIV (zinc-finger). www.clinicaltrials.gov/ct2/show/ NCT00842634
49. Study of autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases in HIV-infected subjects. www.clinicaltrials.gov/ct2/show/ NCT01252641
50. Medco Health Solutions. CCR5 tropism testing for Maraviroc (2004-2012). www.medco.com/medco/corporate/home. jsp?ltSess=y&articleID=CorpPM-Maraviroc 107 Most closely HLA-matched allogeneic irus specific cytotoxic T-lymphocytes (CTL) (CHALLAH). www.clinicaltrials.gov/ct2/show/ NCT00711035